Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy

Author's Avatar
Jun 20, 2023

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced three oral presentations at the Annual Meeting of the European Renal Association (ERA), providing additional support for the efficacy and safety of LUPKYNIS® (voclosporin), a next generation calcineurin inhibitor (CNI) approved in the U.S. and Europe for the treatment of adults with active lupus nephritis (LN).